Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3006486 | 0.92 | TUBB4A (0.53) | MAPTFAAHMEN1KMT2ANPC1 | |
| SCHEMBL4101935 | 0.90 | FAAH (0.54) | MAPTFAAHMEN1KMT2ANPC1 | |
| SCHEMBL4099723 | 0.90 | FAAH (0.54) | MAPTFAAHMEN1KMT2ANPC1 | |
| SCHEMBL2999877 | 0.89 | MAPT (0.61) | MAPTSMN1; SMN2FAAH | |
| SCHEMBL2991095 | 0.89 | FAAH (0.55) | MAPTFAAHMEN1KMT2ANPC1 | |
| SCHEMBL3004943 | 0.88 | TUBB4A (0.52) | MAPTMEN1KMT2ANPC1GAA | |
| SCHEMBL3001895 | 0.88 | PLA2G2A (0.53) | MAPTFAAHMEN1KMT2AALDH1A1 | |
| SCHEMBL4100737 | 0.88 | MAPT (0.49) | MAPTSMN1; SMN2KCNH2ALDH1A1 | |
| SCHEMBL2998998 | 0.88 | P2RX4 (0.48) | MAPTSMN1; SMN2P2RX4MCL1FAAH | |
| SCHEMBL4088958 | 0.87 | FAAH (0.64) | MAPTFAAHMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| EP-2049520-A2 | INDOLE COMPOUNDS | Ironwood Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008019357-A2 | INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | MAPT 2737/4885SMN1; SMN2 4055/4885P2RX4 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.